罗格列酮合用美吡达治疗2型糖尿病观察  

Rosiglitazone Combined with Glipizide Observation of Treatment of Type 2 Diabetes Mellitus

作　　者：姜淑娟 

机构地区：[1]黑龙江省绥化市青冈县人民医院,151600

出　　处：《中国卫生标准管理》2015年第6期240-241,共2页China Health Standard Management

摘　　要：目的对罗格列酮合用美吡达治疗2型糖尿病的治疗效果进行探讨分析。方法将我院收治的42例2型糖尿病患者随机分成研究组和参照组,每组为21例;参照组单独给予美吡达治疗,研究组在给予美吡达基础上加用罗格列酮,12周一疗程,完成一疗程后对比两组治疗前后空腹血糖(FBG)、餐后2h血糖(2h BG)及糖化血红蛋白(Hb Alc)。结果通过治疗后,两组患者的FBG、2h BG及Hb Alc等指标具有降低,且研究组三项指标降幅明显高于参照组,差异明显有统计意义(P<0.05);两组不良反应发生率无显著差异,不具统计意义(P>0.05)。结论罗格列酮合用美吡达相比单用美吡达效果更理想,能有效降低和控制患者血糖水平,不良反应较少,临床推广意义重大。ObjectiveTo rosiglitazone combined with Glipizide in treating type 2 diabetes melitus treatment effect analysis to explore.Methods In our hospital 42 cases of type 2 diabetic patients were randomly divided into the study group and the control group, 21 cases in each group; the reference group of glipizide therapy given alone, the study group was given were based on the use of rosiglitazone.ResultsAfter the therapy, FBG, 2hBG and HbAlc index of the two groups of patients is reduced, and the study group of three indicators fel significantly higher than the reference group, the difference was statisticaly significant （P〈0.05）; the two group the incidence of adverse reaction of no significant difference, with no statistical significance （P〉0.05）. Conclusion Rosiglitazone combined with Glipizide glipizide compared with single effect is more ideal, can effectively reduce and control blood glucose level, less adverse reaction, the clinical significance of the promotion of major.

关 键 词：罗格列酮 美吡达 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]